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Introduction
ABR-215757 (5757) is a quinoline-3-carboxamide currently in clinical development for systemic lupus erythematosus (SLE). In preclinical settings 5757 and structurally related compounds have shown efficacy in several mouse models of T cell-dependent human inflammatory autoimmune disease ( [1] [2] [3] [4] , and unpublished data). This suggested to us that the 5757 treatment might target a common inflammatory mechanism(s) in the various disease models. Along these lines, we have detected a profound reduction of T cell priming in treated mice (our unpublished data). Further, LPS-induced production of the inflammatory cytokine TNF was significantly reduced in 5757-treated mice [5] , suggesting that early steps in T cell activation involving interactions between T cells and antigen-presenting cells might be targeted by 5757-treatment.
It was recently shown that the spleen might function as a reservoir for monocytes, which allows for their rapid recruitment into sites of inflammation [6] . Inflammatory monocytes can generate DCs both in tissue culture and under inflammatory conditions in vivo [7, 8] . In both situations DC-development from monocytes is GM-CSF-dependent and the cells generated functionally resemble the TNF and iNOS producing DC subset (Tip-DCs), which appears in spleen of mice infected with certain pathogens [9, 10] . Monocyte-derived DCs also accumulate in peripheral lymph nodes rapidly after immunization with bacteria or LPS [11] .
Interestingly, these cells were localized in the T cell zones of the lymph nodes and may potentially be involved in T cell activation. 
Materials and Methods

Mice and immunization
C57BL/6 mice and OT-II OVA-specific TCR transgenic mice were used at 7-13 weeks of age. In some experiments, mice were immunized subcutaneously at the base of the tail with an emulsion (100l) of Complete Freunds Adjuvant (CFA) in PBS. The mice were kept in the animal facility at the Biomedical Centre at Lund University. The experiments were approved of by the local ethics comity for use of animals in research.
Cell preparation
Tibia, femur and ilium bone were dissected and gently crushed in Hank's BSS supplemented with 10 mM HEPES (Invitrogen Life Technologies, Paisley, UK) using a mortar and pestle.
The cell suspension was thereafter passed through a 70 m cell strainer and cells washed in
Hank's BSS. Splenic CD4 T cells were purified using CD4 magnetic beads and LS-columns (Miltenyi Biotech, Bergisch Gladbach, Germany). After washing the cells were re-suspended in complete RPMI medium (RPMI 1640 supplemented with 10% FCS, 1 mM sodiumpyruvate, 10 mM HEPES, 100 U/ml penicillin/streptomycin, 50 µM mercaptoethanol; all supplements from Invitrogen Life Technologies) and counted using Trypan blue exclusion.
Cell cultures
BM cells were cultured in 6 well plates (Falcon R Becton Dickinson Labware), 2x10 6 cells/well, in 2 ml complete RPMI medium supplemented with 10 % GM-CSF containing culture supernatant from GM-CSF cDNA transfected J558L cells (prepared in our laboratory), 1 ng/ml recombinant murine G-CSF (rmG-CSF; PeproTech, London, UK), or 80ng/ml M- 
Cell staining and flow cytometry
Cells were re-suspended in FACS buffer (5% FCS and 0.01% NaN 3 in PBS) and stained with antibodies using standard techniques. The following antibodies used in the analyses were prepared in our laboratory: B220-Alexa647, CD11c-Alexa647 and CD11c-biotin. The following antibodies were bought from eBioSciences (Nordic Biosite, Täby, Sweden): experiments cells were labeled with CFSE using a standard protocol. TNF and IL-6 standard was used at concentrations between 4 ng/ml-31.25 pg/ml.
ELISA
Western blot
Cells (1x10 5 ) were lysed in lysis buffer (10% SDS, 20% glycerol, 0.2M Tris-HCl pH 6.8, 0.05% bromophenolblue) containing 100 mM DTT and heated for 10 minutes at 95°C. Equal amounts of lysates were loaded on a 12% SDS-polyacrylamidgel. To detect the S100A8 protein, biotin-conjugated rat-anti-mouse S100A8 antibody was (R&D Systems, Minneapolis, MA) and binding revealed using HRP-anti-biotin antibody (Vector Laboratories Inc., Burlingame, CA). To detect the S100A9 protein, rat-anti-mouse S100A9 antibody (R&D Systems) was used and binding revealed using HRP-conjugated rabbit-anti-rat antibody (Southern Biotechnology Associates Inc.). Actin was detected using rabbit-anti-actin (US Biologicals, Swampscott, MA) and binding revealed using goat-anti-rabbit HRP antibody (BioRad, Richmond, CA). The filters were developed using ECL regent (GE Healthcare, Buckinghamshire, UK)
Quantitative Real-Time PCR
Cells were lysed in TRIzol and total RNA was isolated with a PureLink™ RNA Mini Kit.
cDNA was synthesized with a SuperScript™ III Reverse Transcriptase kit. mRNA was
quantitatively measured with qRT-PCR using a Platinium ® SYBR® Green qPCR supermix-UDG kit (total volume of each sample was 20l). All products were purchased from Invitrogen (Carlsbad, USA). qRT-PCR experiments were performed in triplicate and run on an iCycler MyIQ™ instrument (BioRad, Hercules, CA,). The qRT-PCR was performed with the following primers: S100A8-sense (5'-CCGTCTTCAAGACATCGTTTGA-3'), anti-sense
CTCTTGCTCGAA-3') (obtained from SIGMA Genosys, Canada). Relative S100A8 and S100A9 expression was determined using the formula 2 gene of intrest(Ct)--actin(Ct) .
Statistical analyses
Statistical analyses were performed using unpaired Student's t-test.
Results
Specific effect of 5757 on cell development in BM cell cultures
To determine whether 5757 would influence development of myeloid cells in GM-CSF stimulated BM cell cultures, we supplemented the cultures with various concentrations of the compound ( Figure 1A ). As can be seen, the frequency of CD11c + DCs increased while the frequency of Gr-1 + cells decreased in a dose-dependent way in the supplemented cultures.
This effect was detected at concentrations of the 5757 compound well below those inducing non-specific cell death (100M; data not shown).
We next wanted to determine whether the effect of 5757 on BM cell differentiation in GM-CSF stimulated cultures would be specific for that setting or not. BM cells were therefore Figure 1B ). In contrast, addition of 5757 did not influence the development of Gr-1 + granulocytes in G-CSF stimulated cultures. These data suggest that 5757 has a selective effect on myeloid cell development in growth factor stimulated BM cell cultures.
5757 blocks proliferation cycle entry of Gr-1 + cells
To better define the observed effect of 5757 on cell development in GM-CSF stimulated cultures, we sorted CD117 + CD105 -CD150 -BM cells to enrich for myeloid progenitors [12] .
The sorted cells proliferated extensively in the presence of GM-CSF and a significant fraction of CD11c + could be detected after 6 days of culture. Addition of 5757 to parallel cultures had no detectable effect on the development of CD11c + cells in the cultures (Figure 2A ). We also sorted monocyte populations from BM cells and cultured in the presence GM-CSF. However, under the conditions used here, the monocytes proliferated poorly and the impact of 5757 on their growth could not be addressed (data not shown).
We next investigated whether 5757 might have a direct effect on the Gr-1 + cells. To this end,
we labelled BM cells with CFSE and studied their proliferation in the presence or absence of 5757. As can be seen, addition of 5757 significantly reduced the frequency of Gr-1 + cells that initiated proliferation ( Figure 2B ), while other cells in the Gr-1 + population had proliferated extensively. In contrast, the proliferation of CD11c + cells was not influenced, which is line with the above data (see Figure 2A ). In accordance with these results the kinetics of accumulation of CD11c + cells and reduction of Gr-1 + cells was the same in the presence and absence of 5757 ( Figure 2C ). Taken together these data indicate that 5757 exerts its effect early in the GM-CSF stimulated BM cultures by preventing entry of Gr-1 + cells into the proliferation cycle, while it does not inhibit cell division per se, neither of CD11c + DCs nor of Gr-1 + cells.
Cells developing in the presence of 5757 are functionally normal
It has previously been shown that GM-CSF promotes the generation of TNF and iNOS producing DCs from bone marrow cells in vitro [13, 14] . We next wanted to determine To further confirm the functional competence of these cells, we studied their capacity to stimulate antigen-specific proliferation of OVA-specific TCR transgenic OT-II T cells. Some BM cell cultures were also exposed to LPS, to induce maturation of the CD11c + DCs.
Irrespective of whether the cells were matured with LPS or not, the 5757 exposed cells were 
High-level S100A8 and S100A9 expression in Gr1 + cells
The S100A8 and S100A9 proteins are expressed by monocytes and neutrophils, but not by mature macrophages (reviewed in [15] ). Since supplementation of the GM-CSF stimulated BM cell cultures with 5757 affected Gr-1 + cells and human S100A9 is a molecular target of 14 5757 [5] , we wanted to investigate the expression of S100A8 and S100A9 proteins in these cells. To this end, we sorted various cell populations from the GM-CSF stimulated cultures.
The highest level of S100A8 and S100A9 mRNA and protein expression was detected in the Gr-1 + population ( Figure 4A, B) , while the CD11c + population displayed low expression.
Thus the Gr-1 + cell population that was reduced in the 5757 exposed cultures was also expressing S100A8/A9 at a high level. We also compared the expression levels of S100A8
and S100A9 mRNA in sorted Gr-1 + cells from cultures grown in the presence or absence of 5757. As shown in Figure 4C , there was no detectable effect of 5757 on expression S100A8
and S100A9 mRNA in the Gr-1 + cells.
5757-treatment reduces accumulation of Gr-1 + cells during in vivo inflammation
We next wanted to determine whether 5757-treatment would also have an impact on Gr-1 + cell accumulation in vivo. Previous reports have shown that quinoline-3-carboxamides ameliorate autoimmune disease in experimental models such as experimental autoimmune encephalomyelitis (EAE) [2, 4] . It is well established that subcutaneous immunization with
Complete Freunds Adjuvant (CFA) induces mobilization of myeloid cells in animals, leading to accumulation of CD11b + myeloid cells in the spleen (reviewed in [16] ). Since EAE is induced by immunization with neural antigens emulsified in CFA, we thought that it would be relevant to study the impact of 5757 on accumulation of Gr-1 + cells in CFA-immunized mice.
As expected there was an elevated number of CD11b + cells, most of which are Gr-1 + , in the spleen of CFA immunized mice as compared to controls immunized with Incomplete Freunds Adjuvant (IFA; Figure 5 ). Importantly, the number of Gr-1 + cells was significantly reduced in mice receiving 5757 in the drinking water from the day of immunization. These data indicate that 5757 also reduces the accumulation of Gr-1 + cells during myelopoiesis in vivo.
Discussion
It is well established that monocytes can differentiate to DCs during inflammatory conditions in vivo and in GM-CSF stimulated BM cell cultures in vitro (reviewed in [17] ). The DCs are denoted Tip DCs because of their production of TNF and expression of iNOS [9] and originate from inflammatory CCR2 + monocytes [8] . These cells are important for clearing microbial infections [9] and a recent publication indicated that monocyte derived DCs also accumulate in draining lymph nodes of mice infected with LPS-carrying bacteria [11] . It is tempting to speculate that these monocytes may derive from the splenic monocyte reservoir [6] .
In this report we have studied the impact of the quinoline-3-carboaxamide 5757 on cell development in BM cell cultures stimulated with various growth factors for myeloid cells. We observed a significant increase in CDllc + myeloid DCs and a parallel decrease in Gr-1 + cells in GM-CSF stimulated cultures. Since this was the first example of an in vitro effect of quinoline-3-carboxamides, we thought it was important to further explore this observation. It has been described before that M-CSF can drive the in vitro development of DCs [18] and we found that addition of 5757 to such cultures had a similar but lower effect. In contrast, the compound did not influence the differentiation of granulocytes in G-CSF stimulated cultures.
Thus, the effect of 5757 is specific operating mainly on cell development in GM-CSF stimulated cultures. Further, the effect was dose-dependent and seen at concentrations of 5757 that had no detectable non-specific toxic effect on the BM cells. The cells developing in the presence of 5757 responded to TLR-stimulation similarly to control cells. Further, the cells induced antigen-specific T cell proliferation and in high numbers suppressed T cell proliferation similarly to controls. Thus, by these criteria the cells developing in the presence of 5757 appear to be functionally identical to cells developing in its absence.
We reasoned that 5757 supplementation might either increase the frequency of cells responding to GM-CSF-induced signals by adopting the CD11c + developmental fate or operate directly on Gr-1 + cells. We tested the first possibility by analysing cultures established using sorted CD117 + BM cells that are enriched for myeloid progenitors [12] . There was, however, no significant effect of 5757 on DC development from the BM progenitors, thereby favouring the second possibility. Using CFSE labelled BM cells, we could show that 5757 reduced the fraction of Gr-1 + cells initiating proliferation, while the rest of the cells in the Gr- colony-stimulating activity in vivo [19] and GM-CSF production in cells from BCG-vaccinated humans [20, 21] . The Gr-1 + population contains pro-inflammatory monocytes that are recruited to sites of inflammation [7] as well as other cells such as neutrophils. One would expect that reduction of the number of pro-inflammatory cells would be beneficial in an experimental inflammatory disease such as EAE. We therefore believe that our data offer a possible mechanism for the ameliorating effect of 5757 in experimental autoimmune disease.
In the in vivo treatment experiment, the animals were exposed to 25mg/kg/day of 5757 in the drinking water. It has been shown that mice exposed orally to 30mg/kg/day of 5757 have a We recently reported that in vivo administration of 5757 caused a selective reduction of splenic CD4 + DCs during steady state conditions [22] . The reduction was fully reversible and 5757 had no effect on other immune cells or on DCs in other lymphoid organs. Since 5757 treatment did not influence CD8 + and CD4 -CD8 -splenic DCs, which develop from the same precursors as the CD4 + DCs, we proposed that 5757 would not act at the common DC precursor level [22] . BM cells cultured in vitro in presence of flt3L generate DCs that phenotypically more closely resemble conventional splenic DCs than the cells generated in GM-CSF stimulated cultures [10, 23] . We have also studied the development of DCs in flt3L stimulated BM cultures. However, supplementation of such cultures with 5757 failed to influence DC development (unpublished results), which is in accordance with the lack of activity of 5757 on BM-precursor cells in vivo [22] .
In a recent report we demonstrated that the human S100A9 protein is a molecular target of 5757 [5] . We show in here that the S100A8 and S100A9 genes and the corresponding proteins 
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BM cells were cultured for six days with GM-CSF +/-25 M 5757. Indicated cell populations were isolated by FACS sorting. A and C, S100A8 and S100A9 mRNA expression was determined using qRT-PCR and was normalized to -actin mRNA level. Data indicate mean +/-SD of triplicate samples. B, S100A8 and S100A9 protein expression (5x10 5 cells/lane) was determined using Western blot. C) S100A8 and S100A9 mRNA expression in sorted A.
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